Impact 2: measure the impact of family planning
Our new Impact 2 tool, which launched to the public today, will enable organizations to estimate the wider impact of their family planning programming in developing countries.
Impact 2: An industry-leading tool
Developed in partnership with health economists and demographers, and peer reviewed by the Guttmacher Institute, Population Council, EngenderHealth, Futures Institute, and UNFPA, MSI's Impact 2 projections tool is now being used by 20 organizations, including DFID and USAID.
Impact 2 will make it easier for family planning organisations to measure high level impact without using expensive surveys and complex mathematical modelling.
Our CEO, Dana Hovig commented: “Family planning programs are experienced in measuring program outputs such as commodities and services delivered. However, it’s crucial that we also demonstrate how we impact higher level national health, demographic, and economic goals.
“Because of our investment in developing the user friendly Impact 2 tool, program staff can harness complex datasets to estimate their contribution to national goals, plan for future provision and advocate to donors about the importance of investing in family planning globally.”
Smarter goals, big results
National governments and donors now routinely set high level goals, including increasing contraceptive prevalence rates (CPR) and reducing maternal mortality ratios (MMR).
USAID and UNFPA have both committed to increasing CPR by 2% points annually in targeted countries, and via MDG 5 almost 200 countries have pledged to reduce MMR by three quarters by 2015. Programs need tools, like Impact 2, to estimate how much they can realistically contribute towards these goals.
Impact 2 will allow programs to estimate the number of disability adjusted life-years (DALYs) saved and unplanned pregnancies and births, maternal deaths and unsafe abortions averted based on their actual service provision data.
It will also allow them to estimate economic impact through measures such as cost savings to families and national health systems through reduction in maternal and infant mortality.
Dana Hovig concluded: “We’re delighted that high profile organizations such as DFID and USAID are benefiting from our investment in measuring high level outcomes.
“Being able to estimate how much we can contribute to a government’s goal of increasing CPR to 50%, or whether we could have a greater impact on CPR and MMR if we expanded access to long-acting and permanent methods (LAPMs) is the holy grail the family planning world has been waiting for.”